Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKEEGA vs ADRIAMYCIN PFS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Niraparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that inhibits PARP-1, PARP-2, and PARP-3, leading to DNA damage repair inhibition and apoptosis in BRCA-mutated cells. Abiraterone acetate is a prodrug converted to abiraterone, a CYP17A1 inhibitor that suppresses androgen biosynthesis in testicular, adrenal, and prostate tumor tissues.
Intercalation between DNA base pairs, inhibition of topoisomerase II, and generation of free radicals leading to DNA damage and apoptosis.
Treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (germline and/or somatic) metastatic castration-resistant prostate cancer (m CRPC) in combination with prednisone.
Acute lymphoblastic leukemia,Acute myeloblastic leukemia,Wilms tumor,Neuroblastoma,Soft tissue and bone sarcomas,Breast cancer,Ovarian cancer,Transitional cell bladder cancer,Thyroid cancer,Gastric cancer,Hodgkin lymphoma,Non-Hodgkin lymphoma,Multiple myeloma,Small cell lung cancer
Recommended dose: 240 mg (niraparib) / 500 mg (abiraterone acetate) orally once daily with or without food.
60-75 mg/m² IV every 21 days as a single agent; 40-60 mg/m² IV every 21-28 days in combination regimens. Cumulative lifetime dose not to exceed 450-550 mg/m² (or 400 mg/m² with prior chest irradiation).
Terminal half-life: 17–30 hours (mean ~24 h); allows once-daily dosing but may require dose adjustment in renal impairment.
Triphasic: initial α half-life 30 min (distribution), intermediate β half-life 3-4 hours (metabolism), terminal γ half-life 20-48 hours (prolonged due to extensive tissue binding and slow efflux from tissues).
Niraparib is primarily metabolized by carboxylesterases (CEs) and to a lesser extent by CYP1A2 and CYP2D6. Abiraterone acetate is hydrolyzed to abiraterone, which is then metabolized by CYP3A4 and CYP2D6.
Primarily hepatic metabolism via aldo-keto reductases to doxorubicinol; also undergoes 4-O-demethylation and glucuronidation. CYP450 minimally involved.
Renal: ~85% (primarily as unchanged drug); Biliary/Fecal: ~15%.
Primarily hepatobiliary (∼50% as unchanged drug and metabolites in bile); renal excretion accounts for ∼5-12% over 72 hours; fecal elimination ~40%.
~99% (bound primarily to α1-acid glycoprotein and albumin).
∼70% bound to plasma proteins, primarily albumin; binding is concentration-dependent and saturable at high doses.
Vd: ~1.5–2.0 L/kg (indicates extensive tissue distribution).
Extensive: 20-30 L/kg (total body water far exceeded, indicating deep tissue compartment binding, especially in liver, spleen, heart, and bone marrow).
Oral: ~90% (high oral bioavailability).
Not bioavailable orally (0%, due to extensive first-pass metabolism and instability in GI tract); administered only intravenously.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min). Not recommended for severe renal impairment (e GFR <30 m L/min) or end-stage renal disease.
No specific dose adjustment recommended for renal impairment; however, monitor for toxicity. GFR < 10 m L/min: consider dose reduction by 50% due to potential accumulation of active metabolites.
Contraindicated in severe hepatic impairment (Child-Pugh class C). No dose adjustment for mild (Child-Pugh class A) or moderate (Child-Pugh class B) impairment; but monitor closely for toxicity.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated or reduce by 75% with extreme caution.
Safety and efficacy not established in pediatric patients; no recommended dose.
30-75 mg/m² IV every 21-28 days; cumulative dose limit 400-550 mg/m². Dose based on body surface area; for infants < 1 year or BSA < 0.5 m², use weight-based dosing: 1-2 mg/kg IV every 21 days.
No specific dose adjustment required. Clinical studies included patients ≥65 years; increased risk of adverse effects such as hypertension, hypokalemia, and fatigue. Monitor renal function and electrolytes regularly.
No specific dose adjustment based on age alone; use with caution due to increased risk of cardiotoxicity and myelosuppression. Consider starting at lower end of dosing range (e.g., 45-60 mg/m² every 21 days) and monitor cardiac function.
AKEEGA can cause severe and persistent hypertension, hypokalemia, and fluid retention due to mineralocorticoid excess, especially in patients with renal impairment. Monitor blood pressure, serum potassium, and fluid status regularly.
Myocardial toxicity (including delayed congestive heart failure) may occur with cumulative doses >550 mg/m²; less if prior mediastinal irradiation. Extravasation causes severe tissue necrosis. Secondary acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) reported. Hepatic impairment requires dose adjustment. Use during pregnancy only if benefit outweighs risk.
Hypertension, hypokalemia, and fluid retention due to mineralocorticoid excess,Adrenocortical insufficiency,Hepatotoxicity,Cardiovascular effects including QT prolongation,Bone marrow suppression (anemia, thrombocytopenia, neutropenia),Fetal harm if used during pregnancy
Cardiotoxicity (cumulative dose-dependent, enhanced by prior chest irradiation, age >70, pre-existing cardiac disease); myelosuppression; extravasation injury; secondary malignancies; tumor lysis syndrome; hepatic impairment; radiation recall; mutagenic and carcinogenic potential; impairment of fertility.
Concomitant use with strong CYP3A4 inducers,Severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease,History of hypersensitivity to niraparib, abiraterone, or any excipient
Hypersensitivity to doxorubicin or any component; severe hepatic impairment; severe myelosuppression; baseline cardiac dysfunction; previous treatment with maximum cumulative doses of doxorubicin or other anthracyclines.
Avoid food and beverages containing grapefruit, grapefruit juice, Seville oranges, and starfruit as they inhibit CYP3A4 and may increase abiraterone exposure. Take AKEEGA on an empty stomach (no food for at least 1 hour before or 2 hours after). Avoid high-fat meals as they increase abiraterone absorption.
Grapefruit and grapefruit juice should be avoided as they may inhibit CYP3A4 metabolism and increase doxorubicin toxicity. No other significant food interactions; maintain adequate hydration and nutrition.
AKEEGA (niraparib and abiraterone acetate) is contraindicated in pregnancy. Based on its mechanism of action and findings in animal studies, niraparib can cause fetal harm. Abiraterone acetate is also associated with fetal risks. First trimester exposure may cause embryofetal lethality and teratogenicity. Second and third trimester exposure may impair fetal adrenal function and androgen-dependent development.
FDA Pregnancy Category D. First trimester: high risk of major congenital malformations (e.g., CNS, cardiovascular) and spontaneous abortion. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal myelosuppression. Avoid use unless maternal benefit outweighs fetal risk.
No data on the presence of niraparib or abiraterone in human milk, effects on breastfed infants, or milk production. Due to the potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 1 month after the last dose. M/P ratio is unknown.
Not recommended. Doxorubicin is excreted into human breast milk; M/P ratio not available. Potential for serious adverse reactions in nursing infants (e.g., immunosuppression, neutropenia). Discontinue breastfeeding during treatment and for at least 10 days after last dose.
No specific dose adjustments are established during pregnancy as AKEEGA is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) may necessitate dose adjustments if used inadvertently, but no data are available. If exposure occurs, cautious monitoring and individualized dosing are recommended.
No established dose adjustments in pregnancy. Pharmacokinetic changes (increased plasma volume, altered protein binding) may require monitoring for toxicity or efficacy. Use lowest effective dose; consider dose reduction for myelosuppression or cardiotoxicity. Administration frequency may be modified based on gestational age and maternal tolerance.
AKEEGA (niraparib and abiraterone acetate) is indicated for BRCA-positive metastatic castration-resistant prostate cancer. Monitor for myelosuppression (CBC at baseline and monthly), hypertension (BP weekly for first month then monthly), hypokalemia, and hepatotoxicity (LFTs at baseline and monthly). CYP3A4 inhibitors increase abiraterone exposure; avoid strong inhibitors or reduce dose. Corticosteroid co-administration (prednisone 5 mg BID) is required to manage mineralocorticoid excess. Niraparib may cause fetal harm; confirm pregnancy status before initiation.
Pre-medicate with antiemetics (e.g., 5-HT3 antagonist) prior to administration. Monitor left ventricular ejection fraction (LVEF) at baseline and periodically due to cumulative dose-related cardiotoxicity (lifetime max 450-550 mg/m2, lower with prior chest radiation). Extravasation causes severe tissue necrosis; administer through a free-flowing IV line. Reduce dose in hepatic impairment (bilirubin >1.2 mg/d L). Observe for urine discoloration (red) for 1-2 days post-infusion. Avoid concurrent use with trastuzumab or other cardiotoxic agents.
Take tablets on an empty stomach, at least 1 hour before or 2 hours after a meal.,Swallow tablets whole; do not crush or chew.,Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit during treatment.,Use effective contraception during treatment and for 4 months after the last dose for females and 3 months for males.,Report signs of bone marrow suppression: fever, bruising, bleeding, or unusual tiredness.,Report symptoms of high blood pressure: severe headache, blurred vision, or chest pain.,Take prednisone exactly as prescribed; do not stop abruptly.,Avoid pregnancy; discuss fertility preservation options before starting treatment.,Take missed doses if within 12 hours of scheduled time; otherwise skip and resume next day.,Store at room temperature; keep in original container.
Doxorubicin may cause temporary reddish discoloration of urine for 1-2 days after treatment; this is harmless.,Report any signs of infection (fever, sore throat), unusual bleeding or bruising, mouth sores, or shortness of breath.,Your heart function will be checked before and during treatment; report any chest pain, palpitations, or swelling of ankles/feet.,This drug can cause nausea and vomiting; you will receive medications to prevent these symptoms.,Avoid pregnancy during treatment; use effective contraception. Doxorubicin can harm a fetus and may cause infertility.,Do not receive live vaccines during chemotherapy. Avoid contact with people who have recently received oral polio vaccine.,Take oral care measures (soft toothbrush, bland rinses) to prevent mouth sores.,Limit intake of grapefruit and grapefruit juice as they may affect the drug's metabolism.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKEEGA vs ADRIAMYCIN PFS, answered by our medical review team.
AKEEGA is a Antineoplastic Combination that works by Niraparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that inhibits PARP-1, PARP-2, and PARP-3, leading to DNA damage repair inhibition and apoptosis in BRCA-mutated cells. Abiraterone acetate is a prodrug converted to abiraterone, a CYP17A1 inhibitor that suppresses androgen biosynthesis in testicular, adrenal, and prostate tumor tissues.. ADRIAMYCIN PFS is a Anthracycline Antineoplastic that works by Intercalation between DNA base pairs, inhibition of topoisomerase II, and generation of free radicals leading to DNA damage and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKEEGA and ADRIAMYCIN PFS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKEEGA is: Recommended dose: 240 mg (niraparib) / 500 mg (abiraterone acetate) orally once daily with or without food.. The standard adult dose of ADRIAMYCIN PFS is: 60-75 mg/m² IV every 21 days as a single agent; 40-60 mg/m² IV every 21-28 days in combination regimens. Cumulative lifetime dose not to exceed 450-550 mg/m² (or 400 mg/m² with prior chest irradiation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKEEGA and ADRIAMYCIN PFS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKEEGA is classified as Category C. AKEEGA (niraparib and abiraterone acetate) is contraindicated in pregnancy. Based on its mechanism of action and findings in animal studies, niraparib can cause fetal harm. Abirate. ADRIAMYCIN PFS is classified as Category C. FDA Pregnancy Category D. First trimester: high risk of major congenital malformations (e.g., CNS, cardiovascular) and spontaneous abortion. Second and third trimesters: risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.